August 12, 2018 – By Ricky Cave
Kepos Capital Lp decreased its stake in Gilead Sciences Inc (GILD) by 14.63% based on its latest 2018Q1 regulatory filing with the SEC. Kepos Capital Lp sold 9,589 shares as the company’s stock declined 17.62% with the market. The hedge fund held 55,946 shares of the health care company at the end of 2018Q1, valued at $4.22 million, down from 65,535 at the end of the previous reported quarter. Kepos Capital Lp who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $99.47 billion market cap company. The stock decreased 1.68% or $1.31 during the last trading session, reaching $76.73. About 4.83M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 4.37% since August 12, 2017 and is uptrending. It has underperformed by 8.20% the S&P500. Some Historical GILD News: 12/04/2018 – STAT Plus: Will this experimental hepatitis C treatment break Gilead’s grip on middle-income countries?; 25/04/2018 – CAFC: GILEAD SCIENCES, INC. v. MERCK & CO., INC. [OPINION] – Appeal #16-2302 – 2018-04-25; 06/03/2018 – Top 3 — #1 Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys $GILD; 18/04/2018 – ASTELLAS PHARMA INC – ASSET TRANSFER WAS COMPLETED ON APRIL 12, 2018; 25/04/2018 – MERCK LOSES BID TO REVIVE $200 MILLION VERDICT AGAINST GILEAD; 15/03/2018 – STAT Plus: HHS is urged to investigate a Gilead hepatitis C patent for failing to disclose federal funding; 02/05/2018 – STAT Plus: Gilead’s ‘trough year’ looking harder to dig out from after miserable first quarter; 16/04/2018 – Gilead’s Complera Rises After 1-Wk Fall, Triumeq Advances: HIV; 01/05/2018 – Gilead Sciences 1Q Rev $5.09B; 21/03/2018 – FOCUS-GlaxoSmithKline prescribes commercial reboot for pharma division
Santa Barbara Asset Management Llc decreased its stake in Abbvie Inc (ABBV) by 19.49% based on its latest 2018Q1 regulatory filing with the SEC. Santa Barbara Asset Management Llc sold 347,805 shares as the company’s stock declined 16.83% with the market. The institutional investor held 1.44 million shares of the major pharmaceuticals company at the end of 2018Q1, valued at $136.01 million, down from 1.78M at the end of the previous reported quarter. Santa Barbara Asset Management Llc who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $145.07 billion market cap company. The stock increased 0.35% or $0.33 during the last trading session, reaching $95.8. About 4.45 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 52.41% since August 12, 2017 and is uptrending. It has outperformed by 39.84% the S&P500. Some Historical ABBV News: 09/04/2018 – Keytruda is already approved to treat several forms of cancer, including advanced melanoma. The drug racked up $3.81 billion in revenue in 2017; 23/05/2018 – MERCK & CO – SUBMITTED SBLA FOR KEYTRUDA IN COMBINATION TO U.S. FDA AND NEW DATA WILL BE SHARED WITH AGENCY; 09/04/2018 – KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3 KEYNOTE-042 STUDY, SIGNIFICANTLY IMPROVING OS AS FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC PATIENTS EXPRESSING P…; 22/03/2018 – AbbVie Leads Market’s Plunge as Bio Blockbusters Face Reckoning; 05/04/2018 – $ABBV $BIIB Settlement on Humira #Biosimilar in Europe -; 02/05/2018 – Positive Federal Legislation Could Lead to Exponential Growth in Marijuana and CBD Industry; 01/05/2018 – ABBVIE SUBMITS MARKETING AUTHORIZATION APPLICATION TO EMA FOR; 08/05/2018 – OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of lmmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer; 17/05/2018 – Oncolytics Biotech® Announces Collaboration with Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a Phase 2 Second Line Pancreatic Cancer Study; 13/03/2018 – ABBVIE INC – WOMEN IN STUDY WILL CONTINUE IN EITHER POST-TREATMENT FOLLOW-UP OR A BLINDED SIX-MONTH EXTENSION STUDY
More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Gilead Sciences: Stabilisation In Sight” on July 27, 2018, also Seekingalpha.com with their article: “Gilead’s Stock Price Is Ready To Soar” published on July 30, 2018, Nasdaq.com published: “Gilead Sciences (GILD) Q2 Earnings and Revenues Surpass Estimates” on July 25, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Fool.com and their article: “Is Gilead Sciences’ Sudden Change in Leadership a Good Thing?” published on July 30, 2018 as well as Seekingalpha.com‘s news article titled: “Gilead: Is The Drama Over?” with publication date: August 01, 2018.
Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on October, 25. They expect $1.54 EPS, down 30.94% or $0.69 from last year’s $2.23 per share. GILD’s profit will be $2.00B for 12.46 P/E if the $1.54 EPS becomes a reality. After $1.75 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -12.00% negative EPS growth.
Among 32 analysts covering Gilead Sciences (NASDAQ:GILD), 22 have Buy rating, 0 Sell and 10 Hold. Therefore 69% are positive. Gilead Sciences had 135 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Tuesday, May 30 by Maxim Group. Piper Jaffray maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, February 3 with “Overweight” rating. As per Friday, October 27, the company rating was maintained by Jefferies. The company was maintained on Wednesday, August 31 by Jefferies. Leerink Swann maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, February 7. Leerink Swann has “Market Perform” rating and $83 target. Atlantic Securities initiated the shares of GILD in report on Friday, December 18 with “Neutral” rating. The rating was maintained by Oppenheimer with “Outperform” on Wednesday, July 29. On Wednesday, October 4 the stock rating was maintained by Jefferies with “Hold”. Wells Fargo maintained the stock with “Buy” rating in Monday, January 29 report. BMO Capital Markets maintained the shares of GILD in report on Monday, August 28 with “Hold” rating.
Investors sentiment increased to 0.88 in 2018 Q1. Its up 0.08, from 0.8 in 2017Q4. It is positive, as 71 investors sold GILD shares while 519 reduced holdings. 114 funds opened positions while 404 raised stakes. 976.44 million shares or 0.39% more from 972.68 million shares in 2017Q4 were reported. Mechanics Bank & Trust Tru Department accumulated 7,704 shares. Boston Ptnrs reported 8.04M shares. Rnc Cap Mngmt Lc holds 10,905 shares or 0.06% of its portfolio. 49,758 are owned by Oakwood Mgmt Ltd Liability Co Ca. Edgar Lomax Va accumulated 135,150 shares. Dupont Capital Mgmt Corporation invested in 0.03% or 17,450 shares. 76,000 are held by Cincinnati Insurance Co. Legg Mason Asset Mgmt (Japan) Com holds 0.29% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 5,500 shares. 383,491 are owned by Beck Mack Oliver Ltd Com. Systematic Fincl Management Limited Partnership has 28,726 shares for 0.05% of their portfolio. Northeast Inv holds 4,620 shares. Badgley Phelps Bell reported 107,827 shares. Perella Weinberg Partners Capital Limited Partnership has invested 0.12% in Gilead Sciences, Inc. (NASDAQ:GILD). Moreover, Bb&T Corporation has 0.33% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 227,827 shares. Augustine Asset Mgmt reported 2.32% in Gilead Sciences, Inc. (NASDAQ:GILD).
Since February 9, 2018, it had 0 insider purchases, and 17 insider sales for $25.62 million activity. MARTIN JOHN C sold 50,000 shares worth $3.54 million. Cogan John Francis sold 5,833 shares worth $431,117. Shares for $401,566 were sold by Washington Robin L. $1.97M worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Alton Gregg H.
Kepos Capital Lp, which manages about $2.11B and $1.71B US Long portfolio, upped its stake in Red Hat Inc (NYSE:RHT) by 11,449 shares to 34,893 shares, valued at $5.22M in 2018Q1, according to the filing. It also increased its holding in Ishares Etfs/Usa (EWW) by 165,100 shares in the quarter, for a total of 594,047 shares, and has risen its stake in Exelon Corp (NYSE:EXC).
More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Globenewswire.com which released: “SHAREHOLDER ALERT: MRCY GLNCY GLCNF MD FPI FIZZ SBGL ACAD ABBV TTPH RMTI: The Law Offices of …” on August 12, 2018, also Seekingalpha.com with their article: “AbbVie: Fundamental Disconnect” published on July 19, 2018, Seekingalpha.com published: “AbbVie Is Looking For New Growth Before Generic Competitors Roll In” on August 08, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Seekingalpha.com and their article: “Stay Away From Coal Stocks – Cramer’s Lightning Round (8/9/18)” published on August 10, 2018 as well as Seekingalpha.com‘s news article titled: “Citron details rationale for bearish view on AbbVie” with publication date: July 25, 2018.
Investors sentiment decreased to 0.7 in 2018 Q1. Its down 0.10, from 0.8 in 2017Q4. It turned negative, as 61 investors sold ABBV shares while 737 reduced holdings. 127 funds opened positions while 428 raised stakes. 1.06 billion shares or 0.67% less from 1.06 billion shares in 2017Q4 were reported. Moreover, Ssi Management Inc has 0.03% invested in AbbVie Inc. (NYSE:ABBV). Cove Street Capital Limited Liability reported 1,500 shares. 10,413 are held by Mitchell Mcleod Pugh & Williams. Ferguson Wellman Capital Mngmt owns 691,906 shares or 2.32% of their US portfolio. Ohio-based Keybank Association Oh has invested 0.73% in AbbVie Inc. (NYSE:ABBV). Northeast Investment Mngmt holds 10,013 shares. Schwartz Invest Counsel holds 2,400 shares or 0.01% of its portfolio. 1St Source Natl Bank has 0.19% invested in AbbVie Inc. (NYSE:ABBV). Baystate Wealth Ltd Limited Liability Company reported 3,802 shares or 0.05% of all its holdings. First National Bank & Trust Of Newtown stated it has 17,734 shares. Old Republic holds 0.83% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 295,200 shares. Laurel Grove Ltd owns 28,932 shares. Envestnet Asset Mgmt has 0.05% invested in AbbVie Inc. (NYSE:ABBV) for 190,320 shares. Swedbank has 1.38 million shares. Agf America holds 30,808 shares.
Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on October, 26. They expect $2.01 EPS, up 42.55% or $0.60 from last year’s $1.41 per share. ABBV’s profit will be $3.04B for 11.92 P/E if the $2.01 EPS becomes a reality. After $2.00 actual EPS reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 0.50% EPS growth.
Among 25 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 3 Sell and 12 Hold. Therefore 40% are positive. Abbvie Inc had 99 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Monday, November 20 with “Buy”. Bank of America maintained it with “Hold” rating and $12000 target in Monday, March 26 report. SunTrust initiated AbbVie Inc. (NYSE:ABBV) on Wednesday, July 22 with “Buy” rating. The company was maintained on Friday, September 15 by Piper Jaffray. Leerink Swann upgraded the stock to “Outperform” rating in Monday, October 2 report. The firm earned “Buy” rating on Friday, April 13 by Jefferies. The rating was downgraded by PiperJaffray to “Neutral” on Friday, June 1. The stock has “Mkt Perform” rating by Leerink Swann on Tuesday, October 18. The firm earned “Neutral” rating on Friday, October 13 by UBS. The stock has “Hold” rating by Bernstein on Thursday, March 22.
Since February 19, 2018, it had 2 buys, and 10 sales for $26.21 million activity. 5,400 shares were bought by TILTON GLENN F, worth $496,274. GONZALEZ RICHARD A sold $976,084 worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, February 28. RICHMOND TIMOTHY J. had sold 17,588 shares worth $1.75M on Friday, June 15. The insider Schumacher Laura J sold $2.95M. Another trade for 83,574 shares valued at $9.57M was made by ALBAN CARLOS on Wednesday, February 28. The insider SEVERINO MICHAEL sold $311,684.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.